Hsbc Holdings PLC Takes Position in Jazz Pharmaceuticals PLC $JAZZ

Hsbc Holdings PLC bought a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 5,035 shares of the specialty pharmaceutical company’s stock, valued at approximately $858,000.

A number of other hedge funds have also made changes to their positions in the company. Hilltop National Bank bought a new position in Jazz Pharmaceuticals during the 4th quarter valued at about $36,000. LRI Investments LLC bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $38,000. Leonteq Securities AG bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth about $50,000. GoalVest Advisory LLC acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth approximately $51,000. Finally, Danske Bank A S acquired a new stake in shares of Jazz Pharmaceuticals during the third quarter worth approximately $40,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Trading Up 0.5%

JAZZ stock opened at $238.05 on Wednesday. The company has a market cap of $14.95 billion, a P/E ratio of -11,896.55, a PEG ratio of 0.21 and a beta of 0.32. Jazz Pharmaceuticals PLC has a twelve month low of $105.00 and a twelve month high of $250.49. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The business has a fifty day moving average of $234.16 and a 200-day moving average of $199.13.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The business had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%. As a group, equities research analysts expect that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Rick E. Winningham sold 2,741 shares of the company’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $241.57, for a total transaction of $662,143.37. Following the transaction, the director directly owned 9,567 shares in the company, valued at approximately $2,311,100.19. This represents a 22.27% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $240.47, for a total transaction of $1,442,820.00. Following the completion of the transaction, the director directly owned 366,682 shares in the company, valued at $88,176,020.54. This trade represents a 1.61% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,098 shares of company stock worth $3,131,906. Insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Sanford C. Bernstein reissued a “market perform” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, June 9th. Piper Sandler raised their price target on Jazz Pharmaceuticals from $232.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, May 22nd. Bank of America lifted their price objective on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $188.00 to $307.00 in a research note on Tuesday, May 19th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on Jazz Pharmaceuticals from $250.00 to $270.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $254.47.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.